Dr. Djurhuus commented, “I am excited to join Clinical ink at a time when the convergence of digital health, clinical science, and patient‑centric data capture is creating new opportunities. I look forward to helping advance a disease management solution that delivers meaningful impact for patients while strengthening evidence generation for biopharma partners.”
Newsroom
Adherence to treatment plans is essential to optimize clinical outcomes for patients with chronic conditions. SPUR is a unique adherence solution that provides an individual behavioral diagnosis and intervention plan for each patient.
Integration addresses critical need for accurate, real-time automated insulin delivery data in Type 1 Diabetes clinical research
GlucoseReady™ selected as finalist for “Best Digital Health Solution”.
Members from multiple therapeutic areas will incorporate the patient voice into clinical trial technology design.
AI tool provides real time eCOA and connected device operational data insights.
Industry-leading behavioral science tool SPUR™ is validated to predict adherence and will be offered through the Clinical ink technology platform
Clinical ink, a global life science technology company, announces the promotion of John Pappadakis from EVP, Global Business Development to Chief Commercial Officer and Megan Petrylak from EVP, Clinical Operations to Chief Operating Officer.
